Clinical Trial Update: Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

The Phase 1/1b study of TRU-016 in patients with previously treated Chronic Lymphocytic Leukemia or select subtypes of Non-Hodgkin's Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• TRU-016

Snippet

Sponsor: Aptevo Therapeutics | Conditions: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) | Phase 1 | Status: COMPLETED